Cargando…
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response
BACKGROUND: Radium-223 is a bone-seeking, ɑ-emitting radionuclide used to treat men with bone metastases from castration-resistant prostate cancer. Sclerotic bone lesions cannot be evaluated using Response Evaluation Criteria in Solid Tumors. Therefore, imaging response biomarkers are needed. METHOD...
Autores principales: | Parker, Chris, Tunariu, Nina, Tovey, Holly, Alonzi, Roberto, Blackledge, Matthew D, Cook, Gary J R, Chua, Sue, Du, Yong, Hafeez, Shaista, Murray, Iain, Padhani, Anwar R, Staffurth, John, Tree, Alison, Stidwill, Helen, Finch, Jessica, Curcean, Andra, Chatfield, Peter, Perry, Sophie, Koh, Dow-Mu, Hall, Emma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640884/ https://www.ncbi.nlm.nih.gov/pubmed/37788117 http://dx.doi.org/10.1093/jncics/pkad077 |
Ejemplares similares
-
Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223
por: Hijab, Adham, et al.
Publicado: (2021) -
Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014) -
Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015) -
Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015) -
Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)